NANOBIOTIX (EPA:NANO)

PRESS RELEASE

published on 06/02/2024 at 16:00, 1 year 9 months ago

Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy
Nanobiotix announces new data from Study 1100 showing disease control and tumor response in patients with R/M HNSCC treated with RT-activated NBTXR3 followed by anti-PD-1. Investor event scheduled on June 2nd

NANOBIOTIX Study 1100 R/M HNSCC RT-activated NBTXR3 Anti-PD-1
BRIEF

published on 05/28/2024 at 22:20, 1 year 9 months ago

NANOBIOTIX Presents New Data at ASCO 2024

Immunotherapy NANOBIOTIX NBTXR3 ASCO Phase 1
PRESS RELEASE

published on 05/28/2024 at 22:15, 1 year 9 months ago

NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call
Nanobiotix to present new data from Phase 1 immunotherapy program at 2024 ASCO meeting followed by investor conference call. Details for the call provided

Investor Conference Call Immunotherapy ASCO 2024 NANOBIOTIX Phase 1
BRIEF

published on 05/23/2024 at 22:20, 1 year 9 months ago

NANOBIOTIX to Present at the Jefferies Global Healthcare Conference

Biotechnology Cancer Treatment Webcast NANOBIOTIX Jefferies Global Healthcare Conference
PRESS RELEASE

published on 05/23/2024 at 22:15, 1 year 9 months ago

NANOBIOTIX to Present at the Jefferies Global Healthcare Conference
Nanobiotix to present at the Jefferies Global Healthcare Conference on June 5, 2024, with Bart Van Rhijn, CFO, participating in a fireside chat. Company pioneering physics-based approaches for cancer treatment

Cancer Treatment Biotechnology Company NANOBIOTIX Jefferies Global Healthcare Conference Physics-based Approaches
BRIEF

published on 05/21/2024 at 22:20, 1 year 9 months ago

Nanobiotix Announces Advancement in NBTXR3 Development and Strategic Collaboration

Biotechnology Cancer Therapy NANOBIOTIX NBTXR3 Janssen Collaboration
PRESS RELEASE

published on 05/21/2024 at 22:15, 1 year 9 months ago

Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth
Nanobiotix announces progress in global NBTXR3 development collaboration, highlighting robust pipeline and pathway to long-term growth in cancer treatment. Updates include US FDA approvals and strategic study modifications

Cancer Treatment NANOBIOTIX NBTXR3 Global Development FDA Approvals
BRIEF

published on 05/14/2024 at 22:20, 1 year 10 months ago

NANOBIOTIX Launches Phase 2 Lung Cancer Treatment Study with FDA Approval

FDA Phase 2 Study NANOBIOTIX NBTXR3 Lung Cancer
PRESS RELEASE

published on 05/14/2024 at 22:15, 1 year 10 months ago

NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer
Nanobiotix announces US FDA protocol acceptance for new randomized Phase 2 study on NBTXR3 for stage three lung cancer patients

Phase 2 Study NANOBIOTIX NBTXR3 Lung Cancer FDA Protocol

Published on 03/17/2026 at 13:30, 6 hours 40 minutes ago

Hillcrest Energy Technologies Confirms ZVS PCS1000 Prototype on Track for June 2026
Published on 03/17/2026 at 13:30, 6 hours 40 minutes ago

Namibia Critical Metals Welcomes Toyota Tsusho as Strategic Partner in the Lofdal Heavy Rare Earths Project
Published on 03/17/2026 at 13:00, 7 hours 10 minutes ago

Avant Brands Announces Strategic Realignment of European Operations and Reclaims BLK MKT Brand Rights in Germany and Switzerland
Published on 03/17/2026 at 13:00, 7 hours 10 minutes ago

High-Resolution Airborne Survey Completed at Music Valley HREE Project
Published on 03/17/2026 at 12:30, 7 hours 40 minutes ago

Revival Gold Targets Underground Resource Growth With Drilling at Beartrack-Arnett Gold Project in Idaho

View all ACCESSWIRE

Published on 03/17/2026 at 18:07, 2 hours 3 minutes ago

POS-Transaction in Own Shares
Published on 03/17/2026 at 17:58, 2 hours 12 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 03/17/2026 at 17:45, 2 hours 25 minutes ago

FIGEAC AÉRO: THREE NEW WINS IN MEXICO
Published on 03/17/2026 at 15:30, 4 hours 40 minutes ago

Original-Research: Desert Gold Ventures Inc. (von GBC AG): Buy
Published on 03/17/2026 at 15:19, 4 hours 51 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group PLC

View all EQS

Published on 03/17/2026 at 07:00, 13 hours 10 minutes ago

Invitation to the Extraordinary General Meeting of shareholders
Published on 03/16/2026 at 18:00, 1 day 2 hours ago

Disclosure of trading in own shares from 09/03/2026 to 13/03/2026
Published on 03/16/2026 at 17:58, 1 day 2 hours ago

Aéroports de Paris S.A - February 2026 traffic figures
Published on 03/16/2026 at 17:56, 1 day 2 hours ago

Reporting on share buyback transactions carried out between March 9 and March 13, 2026
Published on 03/16/2026 at 17:45, 1 day 2 hours ago

Weekly share buyback

View all LES ECHOS COMFI WIRE

News